Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
The Influence of Five Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Sponsor: NCIC Clinical Trials Group
A observational or N/A phase clinical study on Breast Cancer and Osteoporosis, this trial is completed. The trial is conducted by NCIC Clinical Trials Group and has accumulated 13 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2023 — Jul 2024 [monthly]
Completed
-
Dec 2021 — Sep 2023 [monthly]
Completed
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
May 2020 — Nov 2020 [monthly]
Completed
-
Jun 2018 — May 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NCIC Clinical Trials Group
For direct contact, visit the study record on ClinicalTrials.gov .